Onco Science
BHW OncoScience
Innovating Precision Cancer Care Across the MENA Region
BHW OncoScience is the dedicated oncology and radiotherapy division of Bayerische Heilmittel Wissenschaften GmbH, focused on advancing precision cancer care through cutting-edge technology and clinical expertise. Led by our in-house oncological radiotherapist and co-founder, the unit drives the establishment of specialized cancer treatment centers and manages the exclusive distribution of advanced radiotherapy systems, including Xstrahl devices, across strategic territories such as Egypt and the broader MENA region.
01
Setting New Standards in Radiotherapy Clinics
We are building advanced radiotherapy clinics designed to deliver precise and effective care for dermatological and oncological patients. Our facilities feature the latest superficial and orthovoltage
X-ray technologies, combining cutting-edge equipment with modern clinical practices to ensure safe, high-quality treatments.
03
Trusted, Certified Medical Technologies
Our commitment goes beyond technology. BHW OncoScience supports clinicians and healthcare institutions with training, clinical protocols, and hands-on guidance to ensure therapies are implemented safely and effectively.
By empowering medical professionals with the right knowledge and tools, we help maximize treatment outcomes.
02
Comprehensive Training & Clinical Support
We provide CE-certified, clinically validated medical devices that meet international treatment standards. Each product is rigorously tested to ensure safety, reliability, and optimal performance, giving healthcare professionals the confidence to deliver effective patient care while staying at the forefront of modern oncology and radiotherapy.
04
Making Advanced Therapies Accessible
We provide CE-certified, clinically validated medical devices that meet international treatment standards. Each product is rigorously tested to ensure safety, reliability, and optimal performance, giving healthcare professionals the confidence to deliver effective patient care while staying at the forefront of modern oncology and radiotherapy.
Strategic Scope & Territories
BHW OncoScience develops specialized treatment centers and distributes advanced radiotherapy systems in select markets, with an initial emphasis on Egypt and the wider MENA region. In these territories, the division coordinates with ministries of health, regulators, and hospital groups to align technology deployment with local clinical needs and infrastructure.
Clinical Focus Areas
- Skin oncology (e.g., basal cell carcinoma, squamous cell carcinoma)
- Cutaneous lymphomas and selected benign/precancerous dermatoses (per local guidelines)
- Palliative and symptom-relief indications where superficial or orthovoltage X-ray therapy is clinically appropriate
What BHW OncoScience Provides
- Site needs assessment, patient-volume modeling, and service-line design.
- Room layout guidance and radiation-shielding calculations in collaboration with licensed physics partners.
- Care-pathway mapping from referral to follow-up, including documentation templates and consent forms.
- Support with device registration, importation dossiers, and hospital licensing requirements.
- CE-marked device documentation handling and alignment with international treatment standards.
- Safety culture programs, incident-reporting procedures, and audit readiness.
- Delivery coordination, acceptance testing, and baseline dosimetry / beam characterization with qualified experts.
- Routine QA program setup (daily / weekly / monthly / annual checks), record-keeping, and KPI dashboards.
- Preventive maintenance schedules and service escalation pathways.
- Multidisciplinary training for radiation oncologists, medical physicists, therapists, and nursing staff.
- Standard operating procedures (SOPs), clinical protocols, and patient selection criteria aligned with local standards of care.
- Proctored case starts and post-go-live support.
- Spare parts, consumables, and calibration services coordination.
- Software updates and enhancements where applicable.
- Continuous professional development: workshops, clinical case reviews, and research collaboration avenues.
Quality & Patient Safety
BHW OncoScience embeds quality from day one through structured SOPs, double-check processes, and periodic audits. Facilities are supported to implement robust QA and radiation-safety programs, with traceable documentation and continuous improvement loops.
Access & Impact
By pairing appropriate technology with capacity building, BHW OncoScience helps health systems open or expand radiotherapy services that are:
- Clinically targeted – focused on skin and selected superficial indications.
- Efficient to set up and operate within existing hospital footprints.
- Scalable across regional networks to reduce patient travel and wait times.
Xstrahl Technology in Clinical Practice
Partnership Model
We work with public and private providers, academic centers, and NGOs through flexible models:
- Turnkey clinic enablement.
- Technology distribution with training bundles.
- Long-term managed-service support.
All models are tailored to local regulations and clinical priorities.
KPIs We Help Institutions Track
- Time-to-therapy (referral to first treatment).
- Protocol adherence and QA pass rates.
- Unplanned treatment interruptions and service uptime.
- Patient-reported outcomes and satisfaction metrics.
Next Steps in MENA
BHW OncoScience is actively collaborating with clinical leaders and authorities to expand access to superficial and orthovoltage radiotherapy for skin cancers and cutaneous lymphomas. Pilot reference sites are prioritized to serve as regional training hubs and centers of excellence.
Contact
For more information, collaboration opportunities, or to discuss potential projects, please contact:
Associate Professor Dr. med. Khaled Elsayad
Biography
Dr. Khaled Elsayad is a German-based radiation oncologist of Egyptian origin, currently serving as a senior physician and head of the dermatooncology unit at the Department of Radiation Oncology at the University Hospital Marburg (Universitätsklinikum Gießen-Marburg, UKGM), Germany. He is known for his clinical expertise in advanced radiotherapy techniques and his commitment to fostering German–Egyptian medical collaboration. Beyond his clinical work, he has been active in academic teaching, mentoring, and international exchange initiatives.
Appointments:
Research Focus – Skin and Benign Diseases
Dr. Elsayad’s research includes oncological and non-oncological applications of radiotherapy. In skin diseases, his work has investigated:
- Radiotherapy for cutaneous lymphomas (especially mycosis fungoides and other primary cutaneous T-cell lymphomas).
- Treatment approaches for skin metastases and rare dermatologic malignancies.
In benign diseases, his research has explored:
- Low-dose radiotherapy for inflammatory and degenerative conditions (e.g., plantar fasciitis, epicondylitis).
- Radiotherapy for keloids and other benign fibroproliferative skin disorders.
- Use of radiation in autoimmune-related skin conditions where conventional therapies are insufficient.
Further references: tsebt.eu
Radiotherapy Indications & Future Perspectives in Germany
In Germany, radiotherapy (RT) is not limited to cancer treatment — it is also widely used for selected non-malignant disorders, with around 50,000 patients treated annually. These conditions are typically grouped into:
- Painful degenerative skeletal disorders (e.g., osteoarthritis, heel spur, tennis elbow)
- Hyperproliferative disorders (e.g., keloids, Dupuytren’s contracture, Peyronie’s disease)
- Symptomatic functional disorders (e.g., Graves’ orbitopathy, trigeminal neuralgia)
The approach uses low-dose radiation to reduce inflammation, slow abnormal tissue growth, and relieve pain — often when other treatments have failed. Germany has long-established protocols for these indications, supported by extensive clinical experience and patient-reported benefits, though international adoption varies.
Selected Publications
- Elsayad K et al. Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results from the prospective S-MISR study. JDDG, 2025.
- Elsayad K et al. Low-dose total skin electron beam radiotherapy in stage IB–IIB mycosis fungoides: Results from the prospective S-MISR study. JCO Oncology Advances, 2025.
- Oymanns M et al. Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma. Immunotherapy, 2025.
- Oymanns M et al. Radioimmunotherapy combined with antibody–drug conjugate induced radiosensitization leads to long-term remission in mycosis fungoides. British Journal of Dermatology, 2026.
- Elsayad K et al. Pegylated interferon combined with low-dose total skin electron beam therapy for advanced stage mycosis fungoides: Two case reports and literature review. Advances in Radiation Oncology, 2025.
- Heger A et al. Health-related quality of life in primary cutaneous B-cell lymphoma following local radiotherapy. JAAD International, 2024.
- Elsayad K et al. Ultrahypofractionated low-dose total skin electron beam in advanced-stage mycosis fungoides and Sézary syndrome. IJROBP, 2023.
- Dippel E et al. S2k-Guidelines – Cutaneous lymphomas: Update 2021. JDDG, 2022.